The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs

Historically, advocates of randomized drug treatment trials in oncology contributed to the changing paradigm for testing cancer treatments in the U.S., which led to global efforts to generate evidence of promise in preclinical model systems and translate those findings into improved patient outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Richard M., Wei, Lai, Fernandez, Soledad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599203/
https://www.ncbi.nlm.nih.gov/pubmed/28620092
http://dx.doi.org/10.1634/theoncologist.2017-0153
_version_ 1783264040479358976
author Goldberg, Richard M.
Wei, Lai
Fernandez, Soledad
author_facet Goldberg, Richard M.
Wei, Lai
Fernandez, Soledad
author_sort Goldberg, Richard M.
collection PubMed
description Historically, advocates of randomized drug treatment trials in oncology contributed to the changing paradigm for testing cancer treatments in the U.S., which led to global efforts to generate evidence of promise in preclinical model systems and translate those findings into improved patient outcomes. In the age of genomic medicine, the challenge to speed the evolution of how clinical trials are conducted in patients with cancer continues.
format Online
Article
Text
id pubmed-5599203
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-55992032017-09-21 The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs Goldberg, Richard M. Wei, Lai Fernandez, Soledad Oncologist Editorial Historically, advocates of randomized drug treatment trials in oncology contributed to the changing paradigm for testing cancer treatments in the U.S., which led to global efforts to generate evidence of promise in preclinical model systems and translate those findings into improved patient outcomes. In the age of genomic medicine, the challenge to speed the evolution of how clinical trials are conducted in patients with cancer continues. AlphaMed Press 2017-06-15 2017-09 /pmc/articles/PMC5599203/ /pubmed/28620092 http://dx.doi.org/10.1634/theoncologist.2017-0153 Text en © AlphaMed Press 2017
spellingShingle Editorial
Goldberg, Richard M.
Wei, Lai
Fernandez, Soledad
The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs
title The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs
title_full The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs
title_fullStr The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs
title_full_unstemmed The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs
title_short The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs
title_sort evolution of clinical trials in oncology: defining who benefits from new drugs using innovative study designs
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599203/
https://www.ncbi.nlm.nih.gov/pubmed/28620092
http://dx.doi.org/10.1634/theoncologist.2017-0153
work_keys_str_mv AT goldbergrichardm theevolutionofclinicaltrialsinoncologydefiningwhobenefitsfromnewdrugsusinginnovativestudydesigns
AT weilai theevolutionofclinicaltrialsinoncologydefiningwhobenefitsfromnewdrugsusinginnovativestudydesigns
AT fernandezsoledad theevolutionofclinicaltrialsinoncologydefiningwhobenefitsfromnewdrugsusinginnovativestudydesigns
AT goldbergrichardm evolutionofclinicaltrialsinoncologydefiningwhobenefitsfromnewdrugsusinginnovativestudydesigns
AT weilai evolutionofclinicaltrialsinoncologydefiningwhobenefitsfromnewdrugsusinginnovativestudydesigns
AT fernandezsoledad evolutionofclinicaltrialsinoncologydefiningwhobenefitsfromnewdrugsusinginnovativestudydesigns

Ejemplares similares